COVID-19 Related Inhibitors

The COVID-19 outbreak due to the novel SARS-CoV-2 virus has turned into a global pandemic infecting hundreds of thousands of people worldwide. With a rapid rate of infection and a high mortality rate, it is estimated that the novel COVID-19 can infect millions of people all over the globe. Quick intervention at this stage to curb further spread becomes crucial and can only be achieved through expediting critical life science research. Scientists and clinicians around the world are focusing on understanding the molecular biology and mechanisms adopted by COVID-19, and its lethal mode of action. To understand the virus completely and develop safe therapeutic interventions, scientists require a range of trusted molecular biology reagents such as high-quality recombinant proteins related to SARS-CoV-2 and inhibitors targeting various viral and cellular proteins employed by the virus.

SignalChem, a global leader in cell signaling and protein engineering, has been devoting resources in creating and developing new research tools related to the SARS-CoV-2 virus since the outbreak. With a comprehensive line of recombinant SARS-CoV-2 Spike proteins, RBD fragments, N protein and other related protein products already in production, SignalChem is also focused on exploring other non-conventional therapeutic avenues against the virus. Our robust range of COVID-19 related inhibitors has been studied by researchers for their therapeutic potential in controlling viral replication by modulating the activity of key viral and cellular proteins. These compounds would also enable scientists to study key cellular proteins and molecular cascades employed by SARS-CoV-2 to interact and enter the cells for replication, and facilitate the development of therapeutic interventions against the virus.